More specifically, it seems to be a combination of: documenting the medical needs of patients (probably through intake forms) who are experiencing or have experienced nausea, vomiting, or other drug tolerance-related issues associated with GLP-1s (which are discussed in this Hims paper), and providing personalized compounded semaglutide in doses outside the 10% threshold to address those documented medical needs
FEBS Lett (1995) 358(3):21924
Kinnunen, S
Food intake, particularly carbohydrates and fats, suppresses ghrelin-mediated GH release by up to 80% (Nass et al., J Clin Endocrinol Metab, 2008)
My Take Berberine has real metabolic benefits, particularly for blood sugar regulation and lipid profiles
Semaglutide plans start at approximately $299/month and tirzepatide at $399/month both all-inclusive, meaning medication, shipping, and clinician oversight are bundled with no add-ons